Ameritas Investment Partners, Inc. Inhibrx, Inc. Transaction History

Ameritas Investment Partners, Inc.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$15.75 - $26.31 $12,678 - $21,179	805 Added 30.88%	3,412 $62,000
Q4 2022 Feb 13, 2023	BUY	$20.18 - $33.33 $8,435 - $13,931	418 Added 19.1%	2,607 $64,000
Q2 2021 Aug 06, 2021	BUY	$14.69 - $27.52 $22,152 - $41,500	1,508 Added 221.44%	2,189 $60,000
Q4 2020 Feb 12, 2021	BUY	$15.96 - $50.0 $10,868 - $34,050	681 New	681 $22,000

25.3K

Ticker INBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,057,700
Market Cap $617M
Description
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...

Get notified when there are updates to the investment portfolio of Ameritas Investment Partners, Inc., based on Form 13F filings with the SEC.

Stay updated on Ameritas Investment Partners, Inc. with notifications on news.